Stabilis. Noms commerciaux. 4 mg/ml 22 C mg/ml 4 C ,6 mg/ml -20 C ,62 mg/ml -20 C mg/ml 25 C

Transcription

1 Stabilis Noms commerciaux Lemod Metilbetasone Prednol Solomet Solu-Medrol Solu-Medrone Urbason Serbie Italie Turquie Finlande Afrique du sud, Autriche, Canada, Croatie, Danemark, Finlande, France, Italie, Norvège, Pologne, Portugal, Tchéquie, Slovenie, Suède, Suisse Grande Bretagne, Irlande Autriche, Espagne, Italie Stabilité des solutions 4 mg/ml 22 C mg/ml 4 C ,6 mg/ml -20 C ,62 mg/ml -20 C mg/ml 25 C mg/ml 5 C ,125 mg/ml 22 C ,125 mg/ml 4 C mg/ml 4 C mg/ml 23 C mg/ml 4 C /08/ :40 - Page 1

2 Stabilité en mélange 0,5 & 2 mg/ml 37 C 0,5 & 2 mg/ml 37 C 2,26 mg/ml 22 C 0,04 mg/ml? 2 mg/ml? 0,04 mg/ml? 0,4 & 1,25 mg/ml 24 C 0,04 & 2 mg/ml? 2,26 mg/ml 22 C 0,51 mg/ml 5 C 2,4 mg/ml 20 C-25 C 2,4 mg/ml 4 C 1,2 mg/ml 20 C-23 C Theophylline : 0,4 mg/ml Theophylline : 4 mg/ml Granisetron hydrochloride : 0,056 mg/ml Ranitidine hydrochloride : 0,05 mg/ml Ranitidine hydrochloride : 0,05 & 2 mg/ml Ranitidine hydrochloride : 2 mg/ml Cimetidine hydrochloride : 3 mg/ml Ranitidine hydrochloride : 0,05 & 2 mg/ml Granisetron hydrochloride : 0,15 mg/ml Cytarabine : 3,85 mg/ml Methotrexate sodium : 1,54 mg/ml Ondansetron hydrochloride : 0,16 mg/ml Ondansetron hydrochloride : 0,16 mg/ml Topotecan : 0,028 mg/ml Incompatibilités Allopurinol sodium : 3 mg/ml Amoxicillin sodium / clavulanic acid Amsacrine : 1 mg/ml Caspofungin acetate : 0.7 mg/ml : 20 mg/ml Ceftolozane / tazobactam : 10 / 5 mg/ml : 62 mg/ml Ciprofloxacin lactate : 2 mg/ml Cisatracurium besylate : 2 & 5 mg/ml Daunorubicin hydrochloride : 20 mg/ml Diltiazem hydrochloride : 5 mg/ml : 2.5 mg/ml Diltiazem hydrochloride : 5 mg/ml /08/ :40 - Page 2

3 : 62.5 mg/ml Diltiazem hydrochloride : 5 mg/ml Docetaxel : 0.9 mg/ml Etoposide phosphate : 5 mg/ml Filgrastim : 30 µg/ml Gemcitabine hydrochloride : 38 mg/ml : 20 mg/ml Isavuconazonium sulfate : 1.5 mg/ml Lansoprazole : 0.55 mg/ml : 3 mg/ml Morphine hydrochloride : 20 mg/ml Paclitaxel : 1.2 mg/ml Palonosetron hydrochloride : 50 µg/ml Propofol : 63 mg/ml Propofol Rocuronium bromide Sargramostim : 10 µg/ml Telavancin hydrochloride : 7,5 mg/ml Vancomycin hydrochloride Vinorelbine tartrate : 1 mg/ml Voie d administration Bibliographie Type Source 22 Revue Sewell GJ, Palmer AJ. The chemical and physical stability of three intravenous infusions subjected to frozen storage and microwave thawing. Int J Pharm 1991 ; 72: /08/ :40 - Page 3

4 29 Revue Pinguet F, Rouanet P, Martel P, Fabbro M, Salabert D, Astre C. Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions. J Pharm Sci 1995 ; 84: Revue Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: Revue Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: Revue Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: Revue Strom JG, Miller SW. Stability and compatibility of methylprednisolone sodium succinate and cimetidine hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1991 ; 48: Revue Nahata MC, Morosco RS, Hipple TF. Stability of diluted methylprednisolone sodium succinate injection at two temperatures. Am J Hosp Pharm 1994 ; 51: Revue Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: Revue Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: Revue Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: Revue Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: , Revue Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: Revue Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: Revue Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: Revue Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: Revue Johnson CE, Cohen IA, Michelini TJ, McMahon RE. Compatibility of premixed theophylline and methylprednisolone sodium succinate intravenous admixtures. Am J Hosp Pharm 1987 ; 44: Revue Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: /08/ :40 - Page 4

5 1026 Revue Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: Revue Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: Revue Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: Revue Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: Revue Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: Revue Das Gupta V. Chemical stability of methylprednisolone sodium succinate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes. Int J Pharm Compound 2001 ; 5: Revue Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: Revue Vermeire A, Remon JP. Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone. Int J Pharm 1998 ; 174: Revue Trissel LA, Zhang Y. Stability of methylprednisolone sodium succinate in autodose infusion system bags. J Am Pharm Assoc 2002 ; 42: Revue Bougouin C, Thelcide C, Crespin-Maillard F, Maillard C, Kinowski JM, Favier M. Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers. Am J Health-Syst Pharm 2005 ; 62: Revue Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound 2006 ; 10: Revue Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound ; 12, 3: Revue Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: Revue D Hondt M, Vangheluwe E, Van Dorpe S, Boonen J, Bauters T, Pelfrene B, Vandenbroucke J, Robays H, De Spiegeleer B Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate Am J Health-Syst Pharm 2012 ; 69: Revue Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: Laboratoire Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit. Mylan SAS /08/ :40 - Page 5

6 3564 Laboratoire Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun Laboratoire Daunorubiine (Cérubidine ) - Résumé des caractéristiques du produit Sanofi Aventis France Poster Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear /08/ :40 - Page 6

7 Dictionnaire Antiinflammatoire Injectable Noms commerciaux Stabilité des solutions Contenant Molécule Concentration Température Conservation Heure Biosimilaire Données conflictuelles Bibliographie Verre Eau pour préparation injectable A l abri de la lumière Heure Jour Polyvinyl chlorure Chlorure de sodium 0,9% Polypropylène Non précisée Polyéthylène NaCl 0,9% ou glucose 5% Ethylène vinyl acétate Stabilité en mélange Solvant Molécule Glucose 5% Lumière Aucun Polyolefine Non précisé Incompatibilités Voie d administration Intraveineuse Perfusion intraveineuse Intramusculaire Bibliographie Dictionnaire /08/ :40 - Page 7